NephroGenex: Annual Report 2014 (Nephrogenex) - Mar 27, 2015 - Anticipated expiry of patents licensed by KUMC related to decreased dialysis related amyloidosis or dialysis related increases in permeability of the peritoneal membrane in a dialysis patient by 2016; Anticipated expiry of patents licensed by KUMC for urinary stone disease by 2021; Anticipated expiry of patents licensed by the University of South Carolina for treatment of diabetes associated increases in hypercholesterolemia or hypertriglyceridemia in a diabetic mammal in US by 2016 and ex-US by 2019; Anticipated expiry of patents licensed by SCRF related to treatment or prevention of acute renal injury or acute renal failure by 2026; Anticipated expiry of patents licensed by Vanderbilt University related to amelioration of at least one symptom of kidney disorder associated with oxidative stress, carbonyl stress, or combinations thereof by 2026; Anticipated expiry of patents licensed by VU for IV formulation by 2026
Anticipated patent expiry • Renal Disease
|